AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21663698 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral and physical activity program (12 weeks of supervised exercise sessions and unsupervised physical activity)
Number of subjects: 110
Study 21663698 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control condition)
Number of subjects: 110
Study 21663698 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral and physical activity program
Number of subjects: 110
Study 19880461 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care treatment
Number of subjects: 0
Study 19880461 — intervention group
Group type: COMPARATOR
Intervention: Specialty care treatment
Number of subjects: 0
Study 17005105 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 10
Study 17005105 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 10
Study 17005105 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication (both pramipexole and amantadine)
Number of subjects: 10
Study 17005105 — intervention group
Group type: COMPARATOR
Intervention: Amantadine vs Pramipexole
Number of subjects: 10
Study 15851214 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm-control strategy
Number of subjects: 4060
Study 15851214 — intervention group
Group type: COMPARATOR
Intervention: Rate-control strategy
Number of subjects: 4060
Study 15851214 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite endpoint of CV hospitalization and death
Number of subjects: 4060
Study 10764718 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN) alpha for three or six months
Number of subjects: 107
Study 10764718 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN) alpha
Number of subjects: 107
Study 10764718 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 107
Study 9077538 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (Ca-suppl.) with 850 mg of calcium daily for 1 year
Number of subjects: 149
Study 9077538 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no calcium supplementation)
Number of subjects: 149
Study 9077538 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (Ca-suppl.)
Number of subjects: 149
Study 8103528 — intervention group
Group type: EXPERIMENTAL
Intervention: Gepirone after a standard high-fat breakfast
Number of subjects: 20
Study 8103528 — intervention group
Group type: COMPARATOR
Intervention: Gepirone after fasting
Number of subjects: 20
Study 8103528 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-PP after a standard high-fat breakfast
Number of subjects: 20
Study 8103528 — intervention group
Group type: COMPARATOR
Intervention: 1-PP after fasting
Number of subjects: 20
Study 2998297 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous sutures using polyglycolic acid
Number of subjects: 3135
Study 2998297 — intervention group
Group type: COMPARATOR
Intervention: Interrupted sutures using polyglycolic acid
Number of subjects: 3135
Study 30047245 — intervention group
Group type: EXPERIMENTAL
Intervention: 60‐mg iron and folic acid (IFA)
Number of subjects: 1379
Study 30047245 — intervention group
Group type: EXPERIMENTAL
Intervention: 20‐mg iron plus 17 micronutrients in a capsule (MMN)
Number of subjects: 1379
Study 30047245 — intervention group
Group type: EXPERIMENTAL
Intervention: lipid‐based nutrient supplement (LNS; 118 kcal) with 20‐mg iron plus 21 micronutrients, protein, and fat
Number of subjects: 1379
Study 26787022 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine buccal infiltration
Number of subjects: 156
Study 26787022 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine inferior alveolar nerve block
Number of subjects: 156
Study 24345172 — intervention group
Group type: EXPERIMENTAL
Intervention: Syntactic processing task in semantic PPA group
Number of subjects: 44
Study 24345172 — intervention group
Group type: COMPARATOR
Intervention: Syntactic processing task in control group
Number of subjects: 44
Study 24345172 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrophic left anterior temporal lobe (ATL) in semantic PPA patients
Number of subjects: 44
Study 24345172 — intervention group
Group type: EXPERIMENTAL
Intervention: Preserved functionality of intact left frontal regions and moderately atrophic left posterior temporal regions in semantic PPA
Number of subjects: 44
Study 21449784 — intervention group
Group type: EXPERIMENTAL
Intervention: Boceprevir plus peginterferon-ribavirin for 32 weeks
Number of subjects: 403
Study 21449784 — intervention group
Group type: EXPERIMENTAL
Intervention: Boceprevir plus peginterferon-ribavirin for 44 weeks
Number of subjects: 403
Study 21449784 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus peginterferon-ribavirin for 44 weeks (Control group)
Number of subjects: 403
Study 21449784 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (boceprevir plus peginterferon-ribavirin) for patients with undetectable HCV RNA at week 8
Number of subjects: 403
Study 21449784 — intervention group
Group type: EXPERIMENTAL
Intervention: Boceprevir groups (group 2 and group 3)
Number of subjects: 403
Study 21449784 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin administration in boceprevir-treated patients
Number of subjects: 403
Study 16056097 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 g acidic oligosaccharides
Number of subjects: 46
Study 16056097 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 0.2 g acidic oligosaccharides and 0.6 g neutral oligosaccharides
Number of subjects: 46
Study 16056097 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin (control)
Number of subjects: 46
Study 12413624 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75‐mg levonorgestrel 12 h apart (group A)
Number of subjects: 1118
Study 12413624 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5‐mg levonorgestrel (group B)
Number of subjects: 1118
Study 12413624 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 1118
Study 9421373 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 (50 pmol x kg-1 x min-1)
Number of subjects: 8
Study 7652667 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiochemotherapy (2‐course radiation treatment of 60 to 70 Gy total dose in combination with mitomycin C and 5‐fluorouracil)
Number of subjects: 31
Study 7652667 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy only (2 patients)
Number of subjects: 31
Study 2503723 — intervention group
Group type: EXPERIMENTAL
Intervention: buserelin (500 micrograms daily subcutaneously) and nilutamide (300 mg daily by mouth)
Number of subjects: 36
Study 2503723 — intervention group
Group type: COMPARATOR
Intervention: buserelin and placebo
Number of subjects: 36
Study 412610 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% aqueous solution of sodium cromoglycate delivered by a metered dose nasal spray
Number of subjects: 44
Study 412610 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 44
Study 29791738 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse home visiting (NHV) program (right@home)
Number of subjects: 0
Study 27599224 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength at Home Couples
Number of subjects: 69
Study 27599224 — intervention group
Group type: COMPARATOR
Intervention: Supportive prevention
Number of subjects: 69
Study 23909699 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg intranasal SB‐705498
Number of subjects: 0
Study 23909699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22981005 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration platform exercise (35 Hz, 2 mm)
Number of subjects: 48
Study 22981005 — intervention group
Group type: COMPARATOR
Intervention: Control exercise (nonvibrating platform)
Number of subjects: 48
Study 20860277 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction diathermy
Number of subjects: 64
Study 20860277 — intervention group
Group type: COMPARATOR
Intervention: Curettage
Number of subjects: 64
Study 18394012 — intervention group
Group type: EXPERIMENTAL
Intervention: 6, 12, 24 and 48 microg rac-formoterol
Number of subjects: 20
Study 18394012 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 and 48 microg rac-formoterol
Number of subjects: 20
Study 18394012 — intervention group
Group type: EXPERIMENTAL
Intervention: 48 microg rac-formoterol
Number of subjects: 20
Study 18394012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 18394012 — intervention group
Group type: EXPERIMENTAL
Intervention: rac-formoterol
Number of subjects: 20
Study 16842919 — intervention group
Group type: EXPERIMENTAL
Intervention: University professor
Number of subjects: 117
Study 16842919 — intervention group
Group type: COMPARATOR
Intervention: Graduate research assistant
Number of subjects: 117
Study 12928688 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face consultations
Number of subjects: 80
Study 12928688 — intervention group
Group type: COMPARATOR
Intervention: Telemedicine consultations (torchlight)
Number of subjects: 80
Study 12928688 — intervention group
Group type: COMPARATOR
Intervention: Telemedicine consultations (slit lamp)
Number of subjects: 80
Study 12928688 — intervention group
Group type: COMPARATOR
Intervention: Telemedicine consultations
Number of subjects: 80
Study 11044424 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromagnetic mapping (group II, n=26)
Number of subjects: 50
Study 11044424 — intervention group
Group type: COMPARATOR
Intervention: Conventional fluoroscopy for catheter navigation (group I, n=24)
Number of subjects: 50
Study 8797769 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg/m2, 3-hour infusion
Number of subjects: 11
Study 8797769 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg/m2, 6-hour infusion
Number of subjects: 11
Study 8797769 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 135 mg/m2, 3-hour infusion
Number of subjects: 11
Study 8797769 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel, 24-hour infusion
Number of subjects: 11
Study 1739926 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose megestrol acetate for 1 month
Number of subjects: 0
Study 1739926 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1739926 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose megestrol acetate after crossover from placebo
Number of subjects: 0
Study 6513775 — intervention group
Group type: EXPERIMENTAL
Intervention: 75% normoxic VO2max under normoxia (NVO2N)
Number of subjects: 6
Study 6513775 — intervention group
Group type: EXPERIMENTAL
Intervention: 75% normoxic VO2max under hyperoxia (NVO2H)
Number of subjects: 6
Study 6513775 — intervention group
Group type: EXPERIMENTAL
Intervention: 75% hyperoxic VO2max under hyperoxia (HVO2H)
Number of subjects: 6
Study 6513775 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxia (HVO2max)
Number of subjects: 6
Study 30724465 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegan diet
Number of subjects: 21
Study 30724465 — intervention group
Group type: COMPARATOR
Intervention: Animal diet
Number of subjects: 21
Study 29146042 — intervention group
Group type: EXPERIMENTAL
Intervention: Online computerized cognitive behavioral therapy (MoodGYM) in addition to usual treatment
Number of subjects: 75
Study 29146042 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment
Number of subjects: 75
Study 26947791 — intervention group
Group type: EXPERIMENTAL
Intervention: WLS Forte
Number of subjects: 148
Study 26947791 — intervention group
Group type: EXPERIMENTAL
Intervention: sMVS
Number of subjects: 148
Study 26947791 — intervention group
Group type: COMPARATOR
Intervention: Control (nonuser)
Number of subjects: 148
Study 25358214 — intervention group
Group type: EXPERIMENTAL
Intervention: Early catheter removal (Group B)
Number of subjects: 320
Study 25358214 — intervention group
Group type: COMPARATOR
Intervention: Standard catheter removal (Group A)
Number of subjects: 320
Study 23197910 — intervention group
Group type: EXPERIMENTAL
Intervention: Anion textile
Number of subjects: 52
Study 23197910 — intervention group
Group type: COMPARATOR
Intervention: Pure cotton textile
Number of subjects: 52
Study 19772969 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin therapy (425 mg/d for 2 years, then 850 mg/d for 2 years)
Number of subjects: 38
Study 19772969 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 38
Study 17824901 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin, 225 mg per day
Number of subjects: 2
Study 17824901 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 16205509 — intervention group
Group type: EXPERIMENTAL
Intervention: Semisolid feeding frequency of three times per day
Number of subjects: 20
Study 16205509 — intervention group
Group type: EXPERIMENTAL
Intervention: Semisolid feeding frequency of four times per day
Number of subjects: 20
Study 12137237 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer leaders plus classroom plus environment interventions
Number of subjects: 0
Study 12137237 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom plus environment interventions
Number of subjects: 0
Study 12137237 — intervention group
Group type: EXPERIMENTAL
Intervention: School environment interventions only
Number of subjects: 0
Study 12137237 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 10404363 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact lens overrefraction (CLO)
Number of subjects: 20
Study 10404363 — intervention group
Group type: COMPARATOR
Intervention: Standard keratometry
Number of subjects: 20
Study 7583526 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 1202
Study 7583526 — intervention group
Group type: EXPERIMENTAL
Intervention: Irregular menstruation (presumably due to perimenopause)
Number of subjects: 1202
Study 2406852 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bismuth subsalicylate (600 mg three times daily)
Number of subjects: 49
Study 2406852 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (800 mg/d)
Number of subjects: 49
Study 2406852 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bismuth subsalicylate
Number of subjects: 49
Study 2406852 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 49
Study 7193007 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline pellets
Number of subjects: 0
Study 30144492 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 85
Study 30144492 — intervention group
Group type: COMPARATOR
Intervention: Intranasal placebo
Number of subjects: 85
Study 27959702 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic dose of low-molecular-weight heparin for 8 days after knee arthroscopy (POT-KAST trial)
Number of subjects: 1451
Study 27959702 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic dose of low-molecular-weight heparin during the full period of immobilization due to casting (POT-CAST trial)
Number of subjects: 1451
Study 27959702 — intervention group
Group type: COMPARATOR
Intervention: No anticoagulant therapy (Control group for POT-KAST trial)
Number of subjects: 1451
Study 27959702 — intervention group
Group type: COMPARATOR
Intervention: No anticoagulant therapy (Control group for POT-CAST trial)
Number of subjects: 1451
Study 25964257 — intervention group
Group type: EXPERIMENTAL
Intervention: Slowly progressive weight lifting
Number of subjects: 295
Study 25964257 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 295
Study 23386127 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment plasma EBV(+)
Number of subjects: 460
Study 23386127 — intervention group
Group type: EXPERIMENTAL
Intervention: Month 6 plasma EBV(+)
Number of subjects: 460
Study 23386127 — intervention group
Group type: COMPARATOR
Intervention: Pretreatment plasma EBV(−)
Number of subjects: 460
Study 23386127 — intervention group
Group type: COMPARATOR
Intervention: Month 6 plasma EBV(−)
Number of subjects: 460
Study 23386127 — intervention group
Group type: COMPARATOR
Intervention: EBER-ISH stratification
Number of subjects: 460
Study 21054568 — intervention group
Group type: EXPERIMENTAL
Intervention: PUVA
Number of subjects: 15
Study 21054568 — intervention group
Group type: COMPARATOR
Intervention: NB-UVB
Number of subjects: 15
Study 19583071 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.2 mg)
Number of subjects: 75
Study 19583071 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (900 mg)
Number of subjects: 75
Study 19583071 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 16733374 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha induction (6 MU daily for 2 weeks, then 3 MU daily for 2 weeks, then 3 MU tiw for 20 weeks)
Number of subjects: 151
Study 16733374 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin (1-1.2 g daily for 24 weeks)
Number of subjects: 151
Study 16733374 — intervention group
Group type: COMPARATOR
Intervention: Control group (IFN-alpha 3 MU tiw for 24 weeks)
Number of subjects: 151
Study 16733374 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin addition in patients with genotype 2 or 3
Number of subjects: 151
Study 16733374 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin addition in patients with genotype 1, 4 or 5
Number of subjects: 151
Study 15658735 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle exercises including a strong post-void 'squeeze out' contraction, biofeedback, and lifestyle changes
Number of subjects: 55
Study 15658735 — intervention group
Group type: COMPARATOR
Intervention: Control group advised solely on lifestyle changes
Number of subjects: 55
Study 11728351 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (n = 45): simple approach (main vessel stenting and balloon angioplasty of the side branch)
Number of subjects: 90
Study 11728351 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II (n = 45): 'T' technique (both main vessel and side branch stented)
Number of subjects: 90
Study 11728351 — intervention group
Group type: COMPARATOR
Intervention: Group I (n = 45)
Number of subjects: 90
Study 11728351 — intervention group
Group type: COMPARATOR
Intervention: Group II (n = 45)
Number of subjects: 90
Study 9924265 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mmol/d Ca supplement (about 40 mmol Ca/d)
Number of subjects: 18
Study 9924265 — intervention group
Group type: COMPARATOR
Intervention: Self‐selected diet (about 22 mmol Ca/d)
Number of subjects: 18
Study 7827299 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethadione (0.9-1.5 g daily)
Number of subjects: 30
Study 7827299 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethadione treatment
Number of subjects: 30
Study 7827299 — intervention group
Group type: COMPARATOR
Intervention: Control group (not treated with trimethadione)
Number of subjects: 30
Study 3280609 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine and tinidazole
Number of subjects: 100
Study 3280609 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine and placebo
Number of subjects: 100
Study 3280609 — intervention group
Group type: COMPARATOR
Intervention: Colloidal bismuth subcitrate (CBS) and placebo
Number of subjects: 100
Study 3280609 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (CBS) and tinidazole
Number of subjects: 100
Study 31539060 — intervention group
Group type: EXPERIMENTAL
Intervention: CS200 (200 mg chitosan per kg feed)
Number of subjects: 320
Study 31539060 — intervention group
Group type: COMPARATOR
Intervention: Control (0 mg chitosan per kg feed)
Number of subjects: 320
Study 30579508 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (details not specified)
Number of subjects: 46
Study 30579508 — intervention group
Group type: COMPARATOR
Intervention: Control group (details not specified)
Number of subjects: 46
Study 26863598 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 40 U (FHL, 20 U; GL, 20 U)
Number of subjects: 0
Study 26863598 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 30 U (FHL, 10 U; GL, 20 U)
Number of subjects: 0
Study 26863598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26099138 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (3 µg/kg loading then 0-3 µg/kg/hour)
Number of subjects: 120
Study 26099138 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (200 µg/kg loading then 0-200 µg/kg/hour)
Number of subjects: 120
Study 26099138 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 120
Study 26099138 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 120
Study 22843943 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-dense sequential chemotherapy (DD-CT) with epirubicin followed by paclitaxel every 2 weeks
Number of subjects: 101
Study 22843943 — intervention group
Group type: COMPARATOR
Intervention: Conventionally-dosed chemotherapy (CD-CT) with epirubicin and paclitaxel simultaneously every 3 weeks
Number of subjects: 101
Study 22843943 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-conserving surgery after neoadjuvant chemotherapy
Number of subjects: 101
Study 22843943 — intervention group
Group type: COMPARATOR
Intervention: Mastectomy after neoadjuvant chemotherapy
Number of subjects: 101
Study 22843943 — intervention group
Group type: EXPERIMENTAL
Intervention: Both DD-CT and CD-CT
Number of subjects: 101
Study 19824805 — intervention group
Group type: COMPARATOR
Intervention: Intralipid (group I)
Number of subjects: 120
Study 19824805 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 1 mg.kg(‐1) (group II)
Number of subjects: 120
Study 19824805 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 1.5 mg.kg(‐1) (group III)
Number of subjects: 120
Study 19824805 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2 mg.kg(‐1) (group IV)
Number of subjects: 120
Study 17584933 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional scapular attitudes measured using the Optotrak Probing System in healthy subjects and subjects with shoulder impingement syndrome.
Number of subjects: 23
Study 17584933 — intervention group
Group type: EXPERIMENTAL
Intervention: Method of calculation relative to the trunk at 70 degrees of flexion.
Number of subjects: 23
Study 16436011 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and lifestyle intervention including monthly lecture-discussion sessions for 10 months, small group counseling, and educational materials based on WCRF Diet and Health Recommendations for Cancer Prevention.
Number of subjects: 116